Abstract
Context: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease of 2019 (COVID-19). Pulmonary manifestations have been identified as the common symptom, and patients present a wide range of hematologic changes depending on the flow of the diseases. The interpretation and treatment of hematological complications in COVID-19 patients are very challenging. There are limited guidelines thus far due to the novelty of the disease. Evidence Acquisition: This review summarizes the hematological findings (platelet and coagulation/fibrinolytic) in COVID-19 patients and discusses possible mechanisms for their changes. Results: The results showed that the common findings were thrombocytopenia, elevated D-dimer levels, and prolonged prothrombin time (PT) and partial thromboplastin time (PTT) in severe patients. Conclusions: Attention to hematological changes may be helpful biomarkers in diagnosing and determining patients needing intensive care, as well as monitoring the treatment process and treatment effects on COVID-19 patients.